In 2015, two phase 3 randomized trials (CheckMate 017/057) reported significantly greater efficacy and safety of nivolumab versus docetaxel as second-line treatment for either squamous or non-squamous advanced NSCLC; of note, this efficacy was independent of the PDL1 expression (13, 15). This evidence concerns the gene CD274 and non-small cell lung carcinoma.